Neda Rasouli, MD
Endocrinology, Diabetes & Metabolism · Aurora, CONPI 1336247295
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $126,383 of the $187,988 with a category attached, or 67.2%. 18 manufacturers reported payments, led by Novo Nordisk AS at 34.0% of the total. 2025 is the largest year on record at $53,805, 4.2 times the $12,948 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $686.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$64K
- Eli Lilly$63K
- Novo Nordisk$48K
- Sanofi-aventis U.S. LLC$5K
- Amgen$4K
- Medtronic$2K
- plus $2K from 12 others
Across 4,250 payments — averaging $1564.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3.8M
- Novo Nordisk AS$2.3M
- Novo Nordisk$479K
- AbbVie$101K
- Boehringer Ingelheim$6K
- Boehringer Ingelheim International GmbH$2K
- plus $35 from 1 others
What the payments were for
- Consulting fees$126,38367%
- Speaking & faculty fees$4500%
- Grants$570%
- Travel & lodging$51,28127%
- Food & beverage$9,7345%
- Education$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 25 | $63,843 |
| Eli Lilly | 164 | $62,909 |
| Novo Nordisk | 43 | $48,196 |
| Sanofi-aventis U.S. LLC | 5 | $5,387 |
| Amgen | 3 | $3,756 |
| Medtronic(3 entities) | 19 | $2,219 |
| Abbott | 1 | $300 |
| Biotronik Inc. | 2 | $231 |
| Cvrx, Inc. | 1 | $209 |
| Nevro Corp. | 1 | $150 |
| Cardiovascular Systems Inc. | 1 | $145 |
| Terumo Medical Corporation | 1 | $128 |
| Philips North America LLC | 1 | $125 |
| Rhythm Pharmaceuticals, Inc. | 1 | $118 |
| Bayer | 1 | $111 |
| AbbVie | 3 | $98 |
| Renalytix AI, Inc. | 1 | $34 |
| Mannkind Corporation | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$34,079
- Ozempic$14,839
- MOUNJARO$10,264
- SOLIQUA 100/33$5,076
- TRADJENTA$2,100
- LINQ II$665
- RESOLUTE ONYX$301
- FreeStyle Libre$300
- CoreValve Evolut$273
- Micra$270
- Barostim Neo System$209
- Resolute$154
- Senza Spinal Cord Stimulation System$150
- Diamondback Peripheral$145
- Diamondback Coronary$145
- Glidesheath$128
- Misago$128
- MetaCross$128
- Navicross$128
- (5027) Intact Vascular Und$125
How this compares
$187,988 in reported general payments places this provider in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $54,126 |
| JardianceEmpagliflozin | 16 | $29,786 |
| MounjaroTirzepatide | 13 | $23,896 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $3,245 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 16 | $1,746 |
| Metformin Hcl | 12 | $171 |
| Losartan Potassium | 11 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $48,196 | $54,12634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Aurora
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Halis AkturkAurora$109K
- Robert EckelAurora$66K
- Marc Andre CornierAurora$62K
- Jane ReuschAurora$59K
- James FalkoAurora$45K
- Aaron MichelsAurora$37K
- Margaret WiermanAurora$36K
- Peter GottliebAurora$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.